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Epinephrine: The Drug of Choice for AnaphylaxisVA
Statement of the World Allergy Organization
Stephen F. Kemp, Richard F. Lockey, F. Estelle R. Simons,
on behalf of the World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis
Abstract: Anaphylaxis is an acute and potentially lethal multisystem
allergic reaction. Most consensus guidelines for the past 30 years
have held that epinephrine is the drug of choice and the ﬁrst drug that
should be administered in acute anaphylaxis. Some state that properly
administered epinephrine has no absolute contraindication in this
clinical setting. A committee of anaphylaxis experts assembled by the
World Allergy Organization has examined the evidence from the
medical literature concerning the appropriate use of epinephrine for
anaphylaxis. The committee strongly believes that epinephrine is
currently underused and often dosed suboptimally to treat anaphy-
laxis, is underprescribed for potential future self-administration, that
most of the reasons proposed to withhold its clinical use are ﬂawed,
and that the therapeutic beneﬁts of epinephrine exceed the risk when
given in appropriate intramuscular doses.
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Epinephrine is the treatment of choice and the ﬁrst drugadministered for acute anaphylaxis, as conﬁrmed inter-
nationally by most consensus anaphylaxis guidelines pub-
lished in the English language over the past 30 years.1Y17
Therapeutic recommendations for epinephrine use in anaphy-
laxis are largely based on clinical pharmacology studies,
clinical observation, and animal models.
Anaphylaxis often occurs outside of a medical setting,
for example, after food ingestion or an insect sting, and the
onset may be sudden and without warning. Severity varies
from episode to episode even with an identical stimulus in the
same patient. Recognition and diagnosis of anaphylaxis is
sometimes difﬁcult for health care professionals and for
individuals without medical training.18
Few controlled clinical trials, and no placebo-controlled
trials, have been performed in anaphylaxis because of the
nature of the disease.19 Randomization to a nonepinephrine
treatment would be unethical because of the preponderance of
data showing that expeditious treatment with epinephrine is
optimal, if not critical, for survival in many instances.20Y25 The
following discussion reviews current evidence for the use of
epinephrine in anaphylaxis.
DEFINITION
The traditional nomenclature for anaphylaxis reserves
the term anaphylactic for immunoglobulin E (IgE)Ydependent
reactions and the term anaphylactoid for IgE-independent
events, which are clinically indistinguishable. The World
Allergy Organization, a worldwide federation of national and
regional allergy and clinical immunology societies and
organizations dedicated to raising awareness and advancing
excellence in clinical care, education, research, and training in
allergy and clinical immunology, recommends that this
terminology be replaced with immunologic (IgE-mediated
and non-IgEYmediated [eg, IgG and immune complex
complementYmediated]) and nonimmunologic anaphylaxis.26
Therefore, in this article, the term anaphylaxis refers to both
immunologic and nonimmunologic anaphylaxis.
METHODS
A literature search of Medline (1966 to present) was
conducted using the key words anaphylaxis and epinephrine
and articles from the personal anaphylaxis ﬁle collections of
the authors were also included. Cross-references were
accessed when deemed appropriate. References have been
categorized by degree of evidence, where possible27 (Fig. 1).
ANAPHYLAXIS IN PERSPECTIVE
Anaphylaxis is an acute and potentially lethal multi-
system allergic reaction in which some or all of the following
signs and symptoms occur: diffuse erythema, pruritus,
urticaria and/or angioedema; bronchospasm; laryngeal
edema; hypotension; cardiac arrhythmias; feeling of impend-
ing doom; unconsciousness and shock. Other earlier or
concomitant signs and symptoms can include itchy nose,
eyes, pharynx, genitalia, palms, and soles; rhinorrhea; change
in voice; metallic taste; nausea, vomiting, diarrhea, abdominal
cramps, and bloating; lightheadedness; headache; uterine
cramps; and generalized warmth.
The US National Institute of Allergy and Infectious
Diseases (Bethesda, Md) and the Food Allergy and Anaphy-
laxis Network (Chantilly, Va) convened symposia in 2004 and
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2005, during which an international and interdisciplinary
group of representatives and experts from 16 professional,
government, and lay organizations attempted, among other
tasks, to establish clinical criteria that would increase
diagnostic precision in anaphylaxis.16 The working deﬁnition
proposed is the following: BAnaphylaxis is a serious allergic
reaction that is rapid in onset and may cause death.[ The group
proposed that anaphylaxis is likely to be present clinically if
any one of 3 criteria is satisﬁed within minutes to hours: (1)
acute onset of illness with involvement of skin, mucosal
surface, or both, and at least one of the following: respiratory
compromise, hypotension, or end-organ dysfunction; (2) 2 or
more of the following occur rapidly after exposure to a likely
allergen: involvement of skin or mucosal surface, respiratory
compromise, hypotension, or persistent gastrointestinal symp-
toms; and (3) hypotension develops after exposure to a known
allergen for that patient: age-speciﬁc low blood pressure or
decline of systolic blood pressure of greater than 30%
compared with baseline.16 The group concluded that these
criteria Bare likely to capture more than 95% of cases of
anaphylaxis.[ The implication from this deﬁnition could be
interpreted to mean that more than just cutaneous and other
even less severe symptoms need to be present before
epinephrine is administered. However, the Anaphylaxis Work-
ing Group report also states that, BThere undoubtedly will be
patients who present with symptoms not yet fulﬁlling the
criteria of anaphylaxis yet in whom it would be appropriate to
initiate therapy with epinephrine, such as a patient with a
history of near-fatal anaphylaxis to peanut who ingested
peanut and within minutes is experiencing urticaria and
generalized ﬂushing.[
In summary, anaphylaxis occurs as part of a clinical
continuum. It can begin with relatively minor symptoms and
rapidly progress to a life-threatening respiratory and cardio-
vascular reaction. Delaying treatment until the development of
multiorgan symptoms, as under the clinical criteria for
diagnosis by the Anaphylaxis Working Group report, may be
risky because the ultimate severity of anaphylaxis is difﬁcult
or impossible to predict at the time of onset of the episode.
Therefore, some of the authors and members of the World
Allergy Organization Ad Hoc Committee on Epinephrine and
Anaphylaxis recommend that any symptoms of anaphylaxis,
such as generalized pruritus, erythema, urticaria, and angioe-
dema alone, and any other systemic symptom including those
not involving vital organs, should be treated immediately and
as necessary with appropriate intramuscular doses of epineph-
rine in an attempt to prevent more severe anaphylaxis from
occurring.
Conversely, symptoms clearly attributable to another
diagnosis for which the clinical probability is much higher, for
example, generalized pruritus, urticaria, and angioedema
associated with new-onset acute urticaria and/or angioedema,
or with an exacerbation of chronic urticaria and/or angioe-
dema, do not necessarily have to be treated with epinephrine.
Thus, there are 2 schools of thought as to when
epinephrine should be given intramuscularly for anaphylaxis
or what appear to be early symptoms of anaphylaxis. One
recommends that epinephrine should be given as described, by
the US National Institute of Allergy and Infectious Diseases
and the Food Allergy and Anaphylaxis Network,16 whereas
another group would go even further and recommend that
epinephrine should be administered as early as possible after
the onset of the least serious or minor symptoms, particularly
when the offending agent or allergen is administered
parenterally. Evidence demonstrates that parenteral delivery
of the offending allergen or causative agent is associated with
more rapid absorption and potentially catastrophic anaphylaxis
than the oral route of administration. However, any route of
administration, oral or parenteral, can cause anaphylaxis and
begin with minor symptoms and result in anaphylactic death.
Foods, medications, insect stings, and allergen immu-
notherapy injections are the most common provoking factors
for anaphylaxis, but it can be induced by any agent capable of
producing a sudden degranulation of mast cells or basophils.28
Anaphylaxis caused by diagnostic and therapeutic interven-
tions is almost unavoidable in medical practice and occurs in a
variety of clinical scenarios.16 The lifetime individual risk of
anaphylaxis is presumed to be 1% to 3%, with a mortality
rate of 1%,28 and the prevalence of anaphylaxis may be
increasing.29 Therefore, all physicians must be able to
recognize anaphylaxis, treat it appropriately, and provide
recommendations to prevent future episodes.
Signs and symptoms of anaphylaxis vary, but cutaneous
features (generalized erythema, pruritus, urticaria, and angio-
edema) are the most common overall.28 Reactions may be
immediate and uniphasic, or they may be delayed in onset,
biphasic (recurrent), or protracted. Biphasic anaphylaxis
occurs in 1% to 20% of anaphylaxis, and symptoms may
FIGURE 1. Categorization of evidence. Adapted from Shekelle et al.27
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recur 1 hour to 72 hours (most within 8 hours) after apparent
resolution of the initial phase.30 The severity of the initial
phase of an anaphylactic reaction is not predictive of
either biphasic or protracted anaphylaxis, although failure to
give an adequate dose of epinephrine initially may be
associated with increased risk of biphasic anaphylaxis.
Monitoring of patients for 24 hours or more after apparent
recovery from the initial phase may be necessary in more
severe cases because life-threatening manifestations of
anaphylaxis may recur. Data are limited concerning the
frequency with which 2 or more doses of epinephrine are
needed to treat anaphylaxis (reports range from 16% to 36%),
and multiple cofactors may be involved.31Y33
Respiratory compromise and cardiovascular collapse
cause most fatalities.28,34 An analysis of 202 anaphylaxis
fatalities occurring in the United Kingdom from 1992 to
2001 ascertained that the interval between initial onset of
food anaphylaxis symptoms and fatal cardiopulmonary
arrest averaged 25 to 35 minutes, which was longer than for
insect stings (10Y15 minutes) or for drugs (mean, 5 minutes
in hospital; 10Y20 minutes prehospital).34
Increased vascular permeability during anaphylaxis can
shift up to 35% of intravascular ﬂuid to the extravascular space
within 10 minutes.35 The intrinsic compensatory response to
anaphylaxis (endogenous epinephrine and other catechola-
mines, as well as angiotensin II, endothelin-1, etc) also
inﬂuences the extent of clinical manifestations and, when
adequate, may be lifesaving independent of medical inter-
vention, which sometimes contributes to diagnostic and
therapeutic confusion. Because mast cells accumulate at
sites of coronary atherosclerotic plaques and IgE antibodies
bound to mast cells can trigger mast cell degranulation, some
investigators have suggested that anaphylaxis may lead to
myocardial ischemia by promoting plaque rupture.36,37
Stimulation of the H1 histamine receptor may also produce
coronary artery vasospasm.37,38
PHARMACOLOGY OF EPINEPHRINE
The pharmacology of epinephrine is reviewed in detail
elsewhere (Fig. 2).39,40 At recommended dosages and routes of
administration, the >-adrenergic vasoconstrictive effects reverse
peripheral vasodilation, which alleviates hypotension and also
reduces erythema, urticaria, and angioedema. Local injection of
epinephrinemay alsominimize further absorption of antigen from
a sting or injection, but this has not been studied systematically.
The A-adrenergic properties of epinephrine cause bronchodila-
tion, increase myocardial output and contractility, and suppress
further mediator release from mast cells and basophils.41,42
Epinephrine administered in low concentrations (eg, 0.1 Kg/kg)
paradoxically can produce vasodilation, hypotension, and
increased release of inﬂammatory mediators.39,43
Epinephrine administration enhances coronary blood
ﬂow. Two mechanisms are probably responsible: an increased
duration of diastole compared with systole and a vasodilator
effect caused by increased myocardial contractility. These
actions usually offset the vasoconstrictor effects of epinephr-
ine on the coronary arteries.39,44
Rapid achievement of peak plasma and tissue epinephrine
levels seems to optimize survival because retrospective human
studies demonstrate that delayed administration is associated
with poor outcomes.20,21 However, epinephrine administration
during anaphylaxis is not always effective, and patients may still
die.20Y25 Reasons may be multifactorial and include delayed
administration, inadequate doses, inappropriate route of admin-
istration, use of epinephrine that has passed its expiration date,
leading to inadvertent administration of an inadequate dose, or an
underlying disease, such as poorly controlled asthma, cardiovas-
cular disease, mastocytosis, and perhaps other serious systemic
disorders.40,45 A study done in a canine model also demonstrates
that achievement of peak epinephrine plasma levels and
hemodynamic recovery is not as effective when epinephrine
administration is delayed until hypotension has developed.46
Epinephrine has a relatively narrow therapeutic window
(relative beneﬁt vs risk; Fig. 3). Common pharmacological
effects that occur at recommended doses via any route of
administration include agitation, anxiety, tremulousness,
headache, dizziness, pallor, or palpitations.39 Rarely, and
usually associated with overdosage or overly rapid rate of
intravenous infusion, epinephrine administration might con-
tribute to or cause myocardial ischemia or infarction,47Y52
pulmonary edema,53,54 prolonged QTc (QTc = QT interval
divided by the square root of the RR interval [in seconds] of
the electrocardiogram) interval,55 ventricular arrhythmias,
accelerated hypertension, and intracranial hemorrhage in
adults and children alike.41,56 Nonetheless, some patients
have survived massive overdoses of epinephrine, with no
evidence of myocardial ischemia.57,58 Particularly vulnerable
populations are those individuals at the extremes of age and
those with hypertension, peripheral vascular disease, ischemic
heart disease, or untreated hyperthyroidism (increased number
FIGURE 2. Adrenergic effects of epinephrine. Adapted from Simons.40
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of A-adrenergic receptors in the vasculature of these indivi-
duals render the myocardium more sensitive to A-adrenergic
effects of epinephrine).59 Certain medications might also
increase the risk of adverse events fromdrug interactions.13,18,42,59
Some medications decrease the effectiveness of endogenous
catecholamine stores or exogenously administered epinephrine
(A-adrenergic blockers), interfere with intrinsic compensatory
responses to hypotension (angiotensin-converting enzyme inhi-
bitors and possibly angiotensin II receptor blockers), or impede
epinephrine metabolism and lead to increased plasma and tissue
concentrations (tricyclic antidepressants and monoamine oxidase
inhibitors). The A-adrenergic antagonists and >-adrenergic
antagonists can also potentially exaggerate pharmacological
effects of epinephrine by permitting unopposed >-adrenergic
(vasoconstrictor) and A-adrenergic (vasodilator) effects, respec-
tively. Cocaine and amphetamines sensitize the myocardium to
effects of epinephrine, thus increasing the risk of toxicity.
However, none of these circumstances pose an absolute
contraindication to epinephrine administration for anaphylaxis.13
MANAGEMENT OF ANAPHYLAXIS
Physician and other health care professionals who
perform procedures or administer medications should have
available the basic therapeutic agents used to treat anaphy-
laxis4,7,13: (1) stethoscope and sphygmomanometer; (2)
tourniquets, syringes, hypodermic needles, large-bore needles
(eg, 14- or 16-gauge); (3) injectable aqueous epinephrine
1:1000 (1 mg in 1 mL; physicians are being urged to express
doses in mass concentration, eg, 1 mg in mL, rather than as
ratios, eg, 1:1000, which have been identiﬁed as a source of
dosing errors with epinephrine and other medications); (4)
equipment and supplies for administering supplemental
oxygen; (5) equipment and supplies for administering
intravenous ﬂuids; (6) oral or laryngeal mask airway; (7)
diphenhydramine or similar injectable antihistamine; (8)
ranitidine or other injectable H2 antihistamine; (9) corticoster-
oids for intravenous injection; and (10) vasopressors (eg,
dopamine or norepinephrine). Glucagon, an automatic deﬁ-
brillator, and 1-way valve face mask with oxygen inlet port are
other supplies that some clinicians might ﬁnd desirable
depending on the individual clinical setting.13
Assessment and maintenance of airway, breathing,
circulation, and mentation are necessary before proceeding to
other management steps. Patients are monitored continuously to
facilitate prompt detection of any clinical changes or treatment
complications. Placement of a patient in the recumbent position
with elevation of the lower extremities is strongly recommended
because management in the sitting or upright position has
contributed to poor outcomes in some patients.34
When to Administer Epinephrine
Epinephrine should be administered simultaneously with
the above measures.12Y14 By expert consensus based on
anecdotal evidence, there is no absolute contraindication to
epinephrine administration in anaphylaxis.13 It can be adminis-
tered in doses appropriate for the severity of the reaction,
regardless of the initial signs and symptoms of anaphylaxis. All
subsequent therapeutic interventions depend on the initial
response to epinephrine. Development of toxicity or inadequate
response to epinephrine injections indicates that additional
therapeutic modalities are necessary.13 Table 1 outlines a
sequential approach to anaphylaxis treatment. Modalities used
in concert with epinephrine are reviewed in detail elsewhere.10Y14
Epinephrine Injections
Expert consensus and anecdotal evidence indicate
aqueous epinephrine 1:1000 dilution (1 mg in 1 mL), 0.2 to
0.5 mg (0.01 mg/kg in children; maximum dose, 0.3 mg)
administered intramuscularly every 5 to 15 minutes or as
necessary, depending on the severity of the anaphylaxis,
should be used to control symptoms and sustain or increase
blood pressure.12Y14 Efﬁcacy comparisons of intramuscular
FIGURE 3. Therapeutic window of epinephrine. Adapted from Simons.18
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injections to subcutaneous injections have not been done
during acute anaphylaxis. However, absorption is complete
and more rapid and plasma levels are higher in asymptomatic
adults and children who receive epinephrine intramuscularly
in the anterolateral thigh (vastus lateralis).60,61 In overweight
and obese individuals, the thickness of the subcutaneous fat
pad may preclude intramuscular access.62Y64 Table 2 provides
some examples of clinical scenarios where the pros and cons
of epinephrine use might be weighed.65,66
Epinephrine autoinjectors, which are easy to use and
will inject through clothing, are currently available in 2
ﬁxed doses: 0.15 mg and 0.3 mg. The potential exists for
overdosage in infants receiving the 0.15 mg, overdosage in
some small children receiving the 0.3 mg dose, and for
underdosage in many adolescents receiving the 0.15 mg
dose.17,40 The relative beneﬁts and risks of dosage might vary
with each individual, but autoinjectors with 0.15 mg of
epinephrine are recommended for otherwise healthy children
who weigh 10 to 25 kg (22Y55 lb) and autoinjectors with
0.3 mg of epinephrine for children who weigh approxi-
mately 25 kg (55 lb) or more.17,40 Providing parents with
an epinephrine ampule, syringe, and needle is not an ap-
propriate option unless autoinjectors are not available for
prescription.66
Intravenous Epinephrine
Epinephrine (1:10,000 or 1:100,000 dilutions) should be
administered by infusion during cardiac arrest or to unre-
sponsive or severely hypotensive patients who have failed to
respond to intravenous volume replacement and several
epinephrine injections.13 One group of investigators suggest
TABLE 1. Management of Acute Anaphylaxis
I. Immediate intervention
a. Assessment of airway, breathing, circulation, and adequacy of mentation
b. Administer epinephrine intramuscularly every 5 to 15 minutes, in
appropriate doses, as necessary, depending on the presenting signs and
symptoms of anaphylaxis, to control signs and symptoms and prevent
progression to more severe symptoms, such as respiratory distress,
hypotension, shock, and unconsciousness.
II. Possibly appropriate subsequent measures depending on response
to epinephrine
a. Place patient in recumbent position and elevate lower extremities
b. Establish and maintain airway
c. Administer oxygen
d. Establish venous access
e. Isotonic sodium chloride solution intravenously for fluid replacement
III. Specific measures to consider after epinephrine injections,
where appropriate
a. Consider epinephrine infusion
b. Consider H1 and H2 antihistamines
c. Consider nebulized A2 agonist (eg, albuterol [salbutamol]) for
bronchospasm resistant to epinephrine
d. Consider systemic corticosteroids
e. Consider vasopressor (eg, dopamine)
f. Consider glucagon for patient taking A-blocker
g. Consider atropine for symptomatic bradycardia
h. Consider transportation to an emergency department or an intensive
care facility
i. For cardiopulmonary arrest during anaphylaxis, high-dose epinephrine
and prolonged resuscitation efforts are encouraged, if necessary
(see reference for specific details)
Adapted from Lieberman et al.13
TABLE 2. Clinical Scenarios for Epinephrine Use Outside of a
Medical Facility
For Discussion Purposes
Clinical Findings Use of Epinephrine?
Generalized urticaria develops in a
28-yr-old fire antYallergic
individual stung by ant while
playing in the yard. Currently
receives ant immunotherapy based
on positive skin test response to
fire ant whole body extract but
is not yet at maintenance dosage
(6 wk of therapy on conventional
\buildup schedule).
Pro: inject immediately; past
anaphylaxis and current
findings away from medical
facility
Con: do not inject immediately;
wait for symptoms involving
another organ system
A 45-yr-old yellow jacketYallergic
farmer has just been stung after
disturbing nest with tractor. History
of hypotension and rapid syncope in
past stings. Currently receives
venom immunotherapy but is not
yet at maintenance (last dose was
1 mL [L]). No current symptoms.
Pro: inject immediately in view
of past severe anaphylaxis; low
risk of serious side effects from
injected epinephrine; some risk
of severe symptoms because he
has not reached maintenance
Con: do not inject immediately;
wait for symptoms
A 17-yr-old individual develops
paroxysmal sneezing within
5 min of receiving allergen
immunotherapy injection
Pro: inject immediately; rapid onset
of symptoms may be associated
with severe anaphylaxis;
low risk of serious side
effects from injected epinephrine;
antihistamines are second-line
agents in anaphylaxis
Con: do not inject immediately;
wait for other symptoms if
suspect sneezing could be due
to transient respiratory irritant
exposure or seasonal allergy
exacerbation if it occurs during
pollen season of a pollen-allergic
individual.
A 7-yr-old child with mild
persistent asthma and clinical
history of peanut allergy
(wheeze, hives that Bget
better after vomiting[)
experiences sudden cough and
wheeze while playing outside
15 min after eating a cookie in




Pro: inject immediately; history is
strongly suggestive of past
anaphylaxis; safety of cookie
is uncertain; signs and severity
of anaphylaxis can vary from
episode to episode in the same
individual; delayed treatment or
treating anaphylaxis with
salbutamol (albuterol) alone
could have adverse outcome;
low risk of serious side effects
from injected epinephrine
Con: do not inject immediately;




Anaphylaxis occurs as part of a continuum, and delaying treatment until multiorgan
dysfunction is present is risky. The recommendations in this table apply regardless of
comorbid conditions because there is no absolute contraindication to epinephrine
administration during anaphylaxis. Physicians and other health care professionals should
instruct patients at risk for anaphylaxis outside of a medical facility to err on the side of
caution and self-administer epinephrine if there is any doubt anaphylaxis is either present
or imminent.
Adapted from Sicherer and Simons.65
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that the early use of intravenous epinephrine is safe, effective,
and well tolerated when the rate is titrated to clinical response,
but this has not been evaluated systematically in a cohort study
comparing this modality to epinephrine intramuscular
injections.67
Inhaled Epinephrine
Some physicians recommend inhalation of epinephrine
as an alternative to injection during anaphylaxis, but perioral
paresthesias, bad taste, and gastrointestinal effects are dose-
limiting, and it may not achieve prompt signiﬁcant increases in
plasma epinephrine concentrations.68,69 No direct comparisons
have been made between the inhaled and the intramuscular
routes of epinephrine administration.
FOLLOW-UP AND OBSERVATION
AFTER ANAPHYLAXIS
Observation periods should be individualized and based
on such factors as comorbid conditions and distance from the
patient’s home to the closest emergency facility, particularly
because there are no reliable predictors of biphasic anaphy-
laxis.13 After resolution of the acute episode, patients should
be discharged with an epinephrine autoinjector and properly
instructed on how to self-administer it in case of a subsequent
episode. They should receive an individualized Anaphylaxis
Emergency Action Plan.18 Patients should also have ready
access to emergency medical services to facilitate prompt
transportation to the closest emergency department (ED) for
treatment after injecting the additional epinephrine.
USE OF EPINEPHRINE BY HEALTH
CARE PROFESSIONALS
Numerous guidelines on anaphylaxis have been pub-
lished, but physicians and other health care professionals often
do not follow them. For example, investigators determined by
questionnaire that only 4 (5%) of 78 senior house ofﬁcers
beginning ED responsibilities in the United Kingdom would
administer epinephrine appropriately and with the proper dose
and route of administration, as outlined in the UK Resuscita-
tion Council guidelines on anaphylaxis.70 Other reports have
examined treatment patterns in the ED settings of civilian71
and military hospitals72 in the United States and observed
that epinephrine injections were administered during acute
anaphylaxis to 16% and 50% of patients, respectively, as
recommended by consensus anaphylaxis guidelines. Retro-
spective analysis of a national reporting database on ED visits
in the United States from 1993 to 2004 revealed 12.4 million
allergy-related visits to the ED, approximately 1% of all ED
visits based on International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation coding. Anaphylaxis coding
was rare (0.01% of all ED visits), although epinephrine was
administered in 50% of those coded with anaphylaxis.
Epinephrine administration documented in patients with
acute allergic conditions was infrequent (11%), and the trend
of use declined over the period of interest from 19% to 7%
(P = 0.04).73
Primary care physicians have demonstrated similar
knowledge gaps in their knowledge pertaining to anaphylaxis.
For example, a questionnaire based on the clinical scenario of
a child with peanut-induced anaphylaxis was used in a random
sample of 468 pediatricians in the United States.74 About half
(56%) agreed that the scenario represented anaphylaxis and
that treatment with epinephrine was indicated. Most (81%)
correctly chose to discharge the child home with self-
injectable epinephrine and either to refer to an allergist or to
recommend further diagnostic testing (86%). Similar surveys
have been done in other countries (several studies are cited in
Pongracic and Kim75).
Studies have also demonstrated that many health care
professionals are uncertain about how to use an epinephrine
autoinjector and thus cannot properly instruct their
patients.76,77 Available resources may help physicians develop
treatment plans and resolve any therapeutic quandaries.17,18,65
Examples of written action plans can be downloaded over the
Internet (see Additional Educational Resources).
UNDERUTILIZATION OF EPINEPHRINE BY
PATIENTS, PARENTS, AND CAREGIVERS
Fatalities during witnessed anaphylaxis, most of which
occur outside of a medical facility, usually result from delayed
administration of epinephrine. In a retrospective review of 6
fatal and 7 nonfatal episodes of food-induced anaphylaxis in
children and adolescents, all subjects who survived had
received epinephrine before or within 5 minutes of developing
severe respiratory symptoms. None of the subjects with fatal
attacks received epinephrine before the onset of severe
respiratory symptoms.20 Analysis of data from a national
case registry of fatal food anaphylaxis in the United States
indicates that very few individuals (7/63) had epinephrine
autoinjectors available at the time of fatal reaction.23,25
Similarly, Pumphrey21 determined that although epinephrine
was administered in 62% of the fatal anaphylactic reactions in
the United Kingdom that he reviewed, in only 14% was it
given before cardiac arrest. In a follow-up analysis of 48
cases of fatal food anaphylaxis from 1999 to 2006, Pumphrey
and Gowland24 reported that 19 (40%) had received
epinephrine autoinjectors, but more than one half of the
fatalities occurred in patients whose previous clinical reactions
had been so mild that, in the opinion of the investigators, it was
unlikely that a physician would have prescribed a precau-
tionary epinephrine syringe.
Multiple factors may contribute to the lack of available
epinephrine for administration during anaphylaxis that occurs
outside of a medical facility. An international survey
conducted under the auspices of the World Allergy Organiza-
tion determined that epinephrine autoinjectors were available
in about half of surveyed countries, and that the cost of an
autoinjector in some countries was equivalent to the monthly
salary of an average citizen.78 Of 39 countries, autoinjectors
containing 0.15-mg and 0.3-mg doses were available in 17
(44%) and 22 (56%), respectively.
Adherence to an action plan to keep epinephrine available
at all times and to inject it during anaphylaxis is another concern.
Kemp and colleagues79 determined in a follow-up survey of
patients that 32 (47%) of 68 did not have the recommended
epinephrine autoinjector with them when they again
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experienced anaphylaxis from a previously identiﬁed culprit.
In contrast, 31 (91%) of 34 patients with idiopathic anaphylaxis
(that is, no culprit could be identiﬁed) had epinephrine available
at the time of a subsequent episode. Implementation of an
educational protocol with emphasis on carrying epinephrine
increased the frequency of adherence from 53% to 92% over the
ensuing 10 years.80 Other studies have similarly reported that
50% to 75% of patients prescribed epinephrine carry it with
them, of whom 30% to 40% can demonstrate proper adminis-
tration technique.81Y84 Still others carry epinephrine but choose
not to use it during anaphylaxis32,85Y87 or prefer to seek
emergency medical assistance.21
Few studies thus far have examined management of
anaphylaxis in school or day care settings. These are reviewed
in detail elsewhere.75 Protection of children at risk for
anaphylaxis in school, day care, or other settings requires an
interdisciplinary approach.9 Several resources are available
for help in the school or day care setting (see Additional
Educational Resources).
PRECAUTIONS FOR THE PATIENT AT RISK
FOR ANAPHYLAXIS
Optimizing prevention (Table 3) is crucial because
future anaphylaxis may be fatal despite appropriate manage-
ment. An allergist-immunologist can provide comprehensive
professional advice on these matters and should be consulted
if he/she is not already involved in the anaphylaxis plan of
care. All patients at risk for future anaphylaxis should carry at
least 1 epinephrine syringe and know how to administer it.
CONCLUSIONS
Based on available evidence, the beneﬁt of using
appropriate doses of intramuscular epinephrine in anaphylaxis
far exceeds the risk (evidence category IV). Consensus
opinion and anecdotal evidence recommend epinephrine
administration Bsooner rather than later,[ that is, when the
initial signs and symptoms of anaphylaxis occur, regardless of
their severity, because fatalities in anaphylaxis usually result
from delayed or inadequate administration of epinephrine.
Experts may differ on how they deﬁne the clinical threshold by
which they deﬁne and treat anaphylaxis. However, they have
no disagreement whatsoever that appropriate doses of
intramuscular epinephrine should be administered rapidly
once that threshold is reached. There is no absolute contra-
indication to epinephrine administration in anaphylaxis, and
all subsequent therapeutic interventions depend on the initial
response to epinephrine. Development of toxicity or inade-
quate response to epinephrine injections indicates that
additional therapeutic modalities are necessary. All individuals
at increased risk of anaphylaxis should have an anaphylaxis
action plan and carry epinephrine autoinjectors for self-
administration. Such individuals (and their caregivers, as
appropriate) should be assessed regularly for adherence
with these recommendations and for the ability to demon-





World Allergy Organization (www.worldallergy.org)
Resuscitation Council (www.resus.org.uk/siteindx.htm)
American Academy of Allergy, Asthma, and Immunol-
ogy (AAAAI) (www.aaaai.org)
American College of Allergy, Asthma, and Immunology
(www.acaai.org)
Joint Council of Allergy, Asthma, and Immunology
(www.jcaai.org)




The Web sites of other national and regional allergy/
immunology organizations also provide useful perspectives.
Action Plans for Health Care Professionals
AAAAI (www.aaaai.org/members/resources/anaphylaxis_
toolkit/action_plan.pdf)
Spanish language versions of the following AAAAI
anaphylaxis materials are now available: The AAAAI Anaphy-
laxis Emergency Action Plan, Killer Allergy information page,
AAAAI Anaphylaxis Tips to Remember brochure, and AAAAI
Anaphylaxis Easy Reader page.
FAAN (English language version: www.foodallergy.org/
actionplan.pdf; Spanish language version: www.foodallergy.
org/spanishaction.pdf)
TABLE 3. Preventive Measures to Reduce the Risk
for Anaphylaxis
I. General measures
Obtain thorough history to diagnose life-threatening food or drug allergy
Identify cause of anaphylaxis and those individuals at risk for future attacks
Provide instruction on proper reading of food and medication labels, where
appropriate
Avoidance of exposure to antigens and cross-reactive substances
Optimal management of asthma and coronary artery disease
Implement a waiting period of 20 to 30 min after injections of drugs or other
biologic agents
In the physician’s office, consider a waiting period of 2 h if a patient receives
an oral medication he/she has never previously taken
II. Specific measures for high-risk patients
Individuals at high risk for anaphylaxis should carry self-injectable syringes
of epinephrine at all times and receive instruction on proper use with
placebo trainer
MedicAlert (MedicAlert Foundation, Turlock, Calif) or similar warning
bracelets or chains
Substitute other agents for A-adrenergic blockers, angiotensin-converting
enzyme inhibitors, tricyclic antidepressants, and monoamine oxidase
inhibitors, whenever possible
Agents suspected of causing anaphylaxis should be given orally if possible;
if the intravenous route is needed, a slow supervised rate of administration
is required
Where appropriate, use specific preventive strategies, including pharmaco-
logical prophylaxis, short-term challenge and desensitization, and
long-term desensitization
Modiﬁed from Kemp.88
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School, Child Care, or Camp Settings
New South Wales Department of Health, Anaphylaxis




Information for Patients and Their Families
Anaphylaxis Campaign (www.anaphylaxis.org.uk)
FAAN (www.foodallergy.org)
Global Allergy and Anaphylaxis Links (www.world
allergy.org/links.shtml)
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